Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONFIRMATION-HF: Finerenone and Empagliflozin in Heart Failure
NCT06024746Phase 3Recruiting
- Sponsor
- CPC Clinical Research
- Start
- Jul 2024
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of finerenone, empagliflozin in heart failure (HF), sponsored by CPC Clinical Research. Started Jul 2024; status: recruiting.
02
Drugs
finerenoneempagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06024746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06024746.